Clinical Chemistry Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--Nov 14, 2022--

The "Clinical Chemistry Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

The publisher's Medical Devices sector report provides comprehensive information about the Clinical Chemistry Rapid Tests & POC pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Clinical chemistry rapid tests provide the test results immediately. These tests are used in low resource settings with the help of test strips, tablets and solutions. Clinical chemistry PoC diagnostics are used to determine the concentration or activity of blood gas, electrolytes, metabolites, enzymes, carbohydrates, proteins, lipids and small molecules.

Scope

• Extensive coverage of the Clinical Chemistry Rapid Tests & POC under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Clinical Chemistry Rapid Tests & POC and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment/industry

Reasons to Buy

The report enables you to:

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Clinical Chemistry Rapid Tests & POC under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Clinical Chemistry Rapid Tests & POC Overview

3 Products under Development

3.1 Clinical Chemistry Rapid Tests & POC - Pipeline Products by Stage of Development

3.2 Clinical Chemistry Rapid Tests & POC - Pipeline Products by Territory

3.3 Clinical Chemistry Rapid Tests & POC - Pipeline Products by Regulatory Path

3.4 Clinical Chemistry Rapid Tests & POC - Pipeline Products by Estimated Approval Date

3.5 Clinical Chemistry Rapid Tests & POC - Ongoing Clinical Trials

4 Clinical Chemistry Rapid Tests & POC - Pipeline Products under Development by Companies

4.1 Clinical Chemistry Rapid Tests & POC Companies - Pipeline Products by Stage of Development

4.2 Clinical Chemistry Rapid Tests & POC - Pipeline Products by Stage of Development

5 Clinical Chemistry Rapid Tests & POC Companies and Product Overview

6 Clinical Chemistry Rapid Tests & POC- Recent Developments

7 Appendix

7.1 Methodology

7.2 About the Publisher

7.3 Contact the Publisher

7.4 Disclaimer

Companies Mentioned

• Abreos Biosciences Inc
• Acetaminophen Toxicity Diagnostics, LLC
• Affinergy LLC
• Am Biotechnologies, LLC
• AnaZyme LLC
• Angle Biosciences Inc
• Augurix SA
• Baebies Inc
• Base Pair Biotechnologies Inc
• Biocross SL
• Bioftalmik Applied Research
• Biotech Resources Aust Pty Ltd
• Boditech Med Inc
• Burnet Institute
• Calmark Sweden AB
• Cambridge Diagnostic Imaging Ltd
• Carclo Diagnostic Solutions Ltd
• CardioGenics Inc
• Cellex Inc
• Center for Biomedical Research Network in Bioengineering, Biomaterials and Nanomedicine
• Claremont BioSolutions
• Columbia University
• DiaSys Diagnostic Systems GmbH
• Edan Instruments Inc
• Foundation for Innovative New Diagnostics
• GlucoSentient Inc
• Group K Diagnostics
• Instrumentation Laboratory Co
• IPI Singapore
• IR2Dx Inc.
• Magee-Womens Research Institute
• Massachusetts Institute of Technology
• Medical University of South Carolina
• MiCo BioMed Co Ltd
• Monash University
• Montana State University
• NanoSpeed Diagnostics Inc
• Ohmx Corp
• OPKO Health Inc
• Oxford Immunotec Ltd
• Pennsylvania State University
• PortaScience Inc
• ProciseDx LLC
• Quidel Corp
• SaltCheck Inc (Inactive)
• Seattle Children's Hospital
• SenGenix Inc
• Systagenix Wound Management Ltd
• The University of New South Wales press Limited
• Thermo Fisher Scientific Inc
• Universal Biosensors Inc
• University of Edinburgh
• University of Florida
• University of South Australia
• UrSure Inc

For more information about this report visit https://www.researchandmarkets.com/r/16fyh8

View source version on businesswire.com:https://www.businesswire.com/news/home/20221114005683/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2022.